Stocks and Investing
Stocks and Investing
Wed, September 8, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, September 7, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Maintained (ADCT) at Buy with Decreased Target to $47 on, Sep 7th, 2021
Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $51 to $47 on, Sep 7th, 2021.
Matthew has made no other calls on ADCT in the last 4 months.
There are 3 other peers that have a rating on ADCT. Out of the 3 peers that are also analyzing ADCT, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Matthew
- Kennen MacKay of "RBC Capital" Initiated at Buy and Held Target at $33 on, Monday, August 9th, 2021
- Brian Cheng of "Cantor Fitzgerald" Initiated at Buy and Held Target at $46 on, Tuesday, June 15th, 2021
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $55 on, Friday, May 14th, 2021
Contributing Sources